HIV combination vaccine - GlaxoSmithKline

Drug Profile

HIV combination vaccine - GlaxoSmithKline

Alternative Names: HIV gp120/NefTat/AS02A vaccine - GSK; NefTat + gp120W61D

Latest Information Update: 17 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; International AIDS Vaccine Initiative; National Institute of Allergy and Infectious Diseases
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 17 May 2016 This programme is still active
  • 24 Aug 2011 GlaxoSmithKline completes enrolment in a phase I trial for HIV infections in Kenya, Uganda and Zambia (NCT01264445)
  • 16 Mar 2011 Phase I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top